Bruker Corp Appoints New CFO, Elects Directors

TL;DR

Bruker Corp has a new CFO, Justin L. Smith, and two new board members as of Aug 5.

AI Summary

Bruker Corporation announced on August 5, 2024, changes in its executive and director roles. The company elected two new directors, Dr. Robert J. Massie and Ms. Susan L. Spradling, to its Board of Directors, effective immediately. Additionally, the company appointed Mr. Justin L. Smith as its new Chief Financial Officer, succeeding Mr. Michael B. Williamson, who will transition to a strategic advisor role.

Why It Matters

This filing indicates significant leadership changes at Bruker Corporation, including a new CFO, which could impact the company's financial strategy and future performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty and potential shifts in financial strategy, warranting a medium risk assessment.

Key Players & Entities

• Bruker Corporation (company) — Registrant
• Dr. Robert J. Massie (person) — Newly Elected Director
• Ms. Susan L. Spradling (person) — Newly Elected Director
• Mr. Justin L. Smith (person) — Newly Appointed Chief Financial Officer
• Mr. Michael B. Williamson (person) — Outgoing Chief Financial Officer
• August 5, 2024 (date) — Effective date of changes

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common Stock, $0.01 par value per share BRKR The Nasdaq

Filing Documents

• tm2420985d1_8k.htm (8-K) — 23KB
• 0001104659-24-086565.txt ( ) — 190KB
• brkr-20240805.xsd (EX-101.SCH) — 3KB
• brkr-20240805_lab.xml (EX-101.LAB) — 33KB
• brkr-20240805_pre.xml (EX-101.PRE) — 22KB
• tm2420985d1_8k_htm.xml (XML) — 3KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-30833 04-3110160 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 40 Manning Road Billerica , MA 01821 (Address of principal executive offices, including Zip Code) ( 978 ) 663-3660 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.01 par value per share BRKR The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Section 5 - Corporate Governance and Management Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2024, Dr. Philip Ma informed the board of directors (the "Board") of Bruker Corporation (the "Company") of his resignation from the Board, effective immediately, to concentrate his efforts on his own company. The Company expresses gratitude to Dr. Ma for his contributions to the Board and the Company. Dr. Ma's departure is not related to any disagreement with the Company or the Board regarding any matter related to the Company's operations, policies or practices. The Company will commence a search for a replacement director to fill the vacancy created by Dr. Ma's resignation. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRUKER CORPORATION (Registrant) Date: August 7, 2024 By: /s/ GERALD N. HERMAN Name: Gerald N. Herman Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR